CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Obesity Impairs the Antitumor Activity of CAR-T Cells in Triple-Negative Breast Cancer.
Obesity Impairs the Antitumor Activity of CAR-T Cells in Triple-Negative Breast Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们在此确定了 TNBC 中 B7-H3 表达、肥胖与肿瘤生长速率之间的相关性。
我们已经报道,靶向 B7-H3 的嵌合抗原受体(CAR)T 细胞(B7-H3.CAR)在三阴性乳腺癌(TNBC)的临床前模型中有效,并已启动一项 I 期研究以评估其安全性和有效性。然而,异质性抗原表达和免疫抑制性肿瘤微环境(TME)仍然是有效 CAR-T 细胞治疗的障碍。特别是,肥胖是 TNBC 的一个负面预后因素,部分原因是慢性炎症和适应性免疫反应受损。因此,我们试图确定肥胖是否会影响 B7-H3.CAR-T 细胞的抗肿瘤活性。
我们使用qPCR和western blotting来确定与肥胖相关的细胞因子是否影响TNBC细胞系中B7-H3的表达。此外,我们使用shRNA在同源原位E0771肿瘤模型中抑制B7-H3表达,并测量了对照组和饮食诱导肥胖(DIO)小鼠的肿瘤生长。最后,我们评估了B7-H3.CAR-T 细胞在对照组和DIO小鼠原位移植E0771肿瘤细胞系中的抗肿瘤效果。使用流式细胞术进行了免疫分析。
肥胖相关炎性细胞因子在体外促进人和小鼠 TNBC 细胞中 B7-H3 的表达,并且 B7-H3 表达在体内与肿瘤侵袭性相关。来自对照或 DIO 小鼠的 CAR-T 细胞在体外具有相同的细胞毒性,但来自 DIO 小鼠的活化 T 细胞和 B7-H3.CAR-T 细胞分别显示出转录组变化(富集 Tox2、Prdm1、Batf)和糖酵解能力受损。最后,我们证明肥胖在体内损害 CAR-T 细胞的抗肿瘤作用及应答持久性,并伴有记忆形成近乎完全丧失。
We have reported that chimeric antigen receptor (CAR) T cells targeting B7-H3 (B7-H3.CAR) are effective in a preclinical model of triple negative breast cancer (TNBC), and have initiated a Phase I study to assess safety and efficacy. However, heterogeneous antigen expression and immunosuppressive tumor microenvironments (TME) remain roadblocks for effective CAR-T cell therapy. In particular, obesity represents a negative prognostic factor in TNBC partly due to chronic inflammation and impaired adaptive immune responses. Hence, we sought to determine if obesity can affect the antitumor activity of B7-H3.CAR-T cells.
We used qPCR and western blotting to determine if cytokines associated with obesity affect B7-H3 expression in TNBC cell lines. Furthermore, we used shRNA to suppress B7-H3 expression in a syngeneic orthotopic E0771 tumor model and measured tumor growth in control and diet-induced obese (DIO) mice. Finally, we evaluated the antitumor effects of B7-H3.CAR-T cells in both control and DIO mice orthotopically engrafted with the E0771 tumor cell line. Immune profiling was conducted using flow cytometry.
Obesity-related inflammatory cytokines promote B7-H3 expression in human and murine TNBC cells in vitro and B7-H3 expression correlates with tumor aggressiveness in vivo. CAR-T cells obtained from control or DIO mice were equally cytotoxic in vitro but activated T cells and B7-H3.CAR-T cells obtained from DIO mice show transcriptomic changes (enriched Tox2, Prdm1, Batf ) and impaired glycolytic capacity, respectively. Finally, we demonstrated that obesity impairs CAR-T cell antitumor effects and durability of response in vivo with a near complete loss of memory formation.
Here we identified a correlation between B7-H3 expression, obesity, and rate of tumor growth in TNBC. Furthermore, we showed that obesity constrains both the ability of B7-H3.CAR-T cells to control tumor growth and to elicit durable immunological memory. Taken together, these data identify obesity as an underappreciated and potent modulator of CAR-T cell functionality. WHAT IS ALREADY KNOWN: B7-H3 protein is upregulated in many human malignancies including TNBC and is often associated with worsened outcomes. B7-H3.CAR-T cells show promise in preclinical models of TNBC and entered clinical translation. WHAT THIS STUDY ADDS: This study identifies a previously unknown correlation between obesity, B7-H3 expression, and rate of tumor growth in TNBC. Furthermore, our preclinical model of B7-H3.CAR-T cell therapy demonstrates that obesity negatively affects the antitumor activity of B7-H3.CAR-T cells in TNBC. HOW THIS STUDY AFFECTS OTHER RESEARCH/PRACTICE: This study highlights obesity as an understudied and critically important covariate for adoptive T-cell therapy and demonstrates important links between systemic metabolism and antigen expression. This work paves the way for future mechanistic and translational research into how obesity impacts CAR-T cell functionality.
MEMBER ACCOUNT
登录成功会直接打开下一页。